Cerebras Shares Are Coming Out of Lockup in Waves. Here's the Date That Matters Most.

Cerebras Systems' staged IPO lockup will likely fully expire on Nov. 9, after three additional releases of roughly 19.4 million shares each on Sept. 30, Oct. 14, and Oct. 28. Nearly 113 million of an estimated 171 million early-release shares are already eligible for sale, while the final expiration will unlock all remaining restricted shares, creating a potential supply overhang. Shares trade near $199, down from a first-day peak above $386 but about 7% above the $185 IPO price, despite Q2 revenue growth of 74% to roughly $180 million and $25.4 billion in remaining performance obligations.

Analysis

CBRS is transitioning from scarcity-driven IPO price discovery to a substantially larger effective float, which changes the marginal buyer base more than it changes intrinsic value. The key near-term mechanism is not mechanical selling alone: newly liquid venture and employee holders can monetize into liquidity windows, while market makers will widen risk limits and index/active managers may wait for post-expiry volume before building positions. That can cap rallies through late October even if operating results remain intact, with the largest dislocation likely occurring in the sessions immediately before and after the final unlock rather than precisely on each scheduled date.

The more material fundamental risk is that a concentrated backlog creates a valuation-duration problem: CBRS is being valued on multi-year conversion of contracted demand, but a single customer's deployment timing, financing capacity, or hardware qualification changes could shift recognized revenue and gross-margin absorption sharply. NVDA is the indirect competitive beneficiary if customers treat Cerebras capacity as a second-source experiment rather than a durable architecture shift; any evidence that deployments remain non-recurring would favor incumbent GPU economics and compress CBRS's revenue multiple.

Consensus may overstate the certainty of a final-expiry selloff because much of the supply has already become tradable, and sophisticated holders can pre-hedge or distribute gradually. The cleaner catalyst is therefore Q3: a strong report accompanied by backlog conversion, customer diversification, and no deterioration in gross margin could absorb the remaining supply and create a post-November relief rally. Conversely, weak conversion metrics or an OpenAI-related concentration disclosure would matter far more than the lockup calendar and could reset the stock below its IPO reference level over 1-3 months.

Key Decisions for Investors

• Maintain a tactical underweight/short bias in CBRS into the final October unlocks, but size modestly and cover into Nov. 9 rather than chasing the event; target a 15-20% downside versus a stop on a sustained close above $225 or a material upward revision to revenue/backlog-conversion guidance.
• Do not initiate a directional long solely on a quiet release date. Set a post-Q3 alert to buy CBRS only if quarterly revenue conversion and gross margin meet or exceed guidance, customer concentration declines, and average daily dollar volume demonstrates absorption of new float; this is a 6-18 month fundamental position, not a lockup trade.
• For AI exposure, favor a relative-value pair of long NVDA / short CBRS in equal beta-adjusted notional through Q3 results. The pair benefits if enterprise buyers continue standardizing on CUDA/GPU infrastructure or if CBRS's concentrated backlog converts more slowly; reassess if CBRS discloses meaningful non-OpenAI wins or sustained margin outperformance.
• Avoid CBRS options until implied volatility, open interest, and stock-borrow availability are verified. If put skew remains modest ahead of the final expiry, a defined-risk put spread expiring after Q3 is preferable to outright shorting because borrow costs and squeeze risk can dominate a widely anticipated supply event.